Calton & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.21M | Sell |
4,822
-1,597
| -25% | -$344K | 0.18% | 112 |
|
|
2026
Q1 | $1.4M | Sell |
6,419
-811
| -11% | -$180K | 0.2% | 102 |
|
|
2025
Q4 | $1.65M | Buy |
7,230
+179
| +3% | +$40.8K | 0.24% | 82 |
|
|
2025
Q3 | $1.63M | Buy |
7,051
+1,194
| +20% | +$243K | 0.25% | 81 |
|
|
2025
Q2 | $1.09M | Sell |
5,857
-319
| -5% | -$59.3K | 0.19% | 98 |
|
|
2025
Q1 | $1.29M | Buy |
6,176
+2,615
| +73% | +$508K | 0.3% | 70 |
|
|
2024
Q4 | $633K | Sell |
3,561
-847
| -19% | -$156K | 0.28% | 87 |
|
|
2024
Q3 | $871K | Buy |
4,408
+804
| +22% | +$150K | 0.33% | 67 |
|
|
2024
Q2 | $618K | Sell |
3,604
-383
| -10% | -$63.4K | 0.31% | 78 |
|
|
2024
Q1 | $726K | Sell |
3,987
-979
| -20% | -$169K | 0.35% | 70 |
|
|
2023
Q4 | $770K | Buy |
4,966
+2,393
| +93% | +$349K | 0.31% | 74 |
|
|
2023
Q3 | $384K | Sell |
2,573
-2,291
| -47% | -$336K | 0.56% | 47 |
|
|
2023
Q2 | $655K | Sell |
4,864
-69
| -1% | -$10.1K | 0.31% | 79 |
|
|
2023
Q1 | $786K | Buy |
4,933
+61
| +1% | +$9.33K | 0.36% | 68 |
|
|
2022
Q4 | $787K | Buy |
4,872
+681
| +16% | +$104K | 0.3% | 77 |
|
|
2022
Q3 | $562K | Sell |
4,191
-251
| -6% | -$36K | 0.32% | 79 |
|
|
2022
Q2 | $680K | Sell |
4,442
-1,132
| -20% | -$173K | 0.38% | 68 |
|
|
2022
Q1 | $903K | Sell |
5,574
-665
| -11% | -$96.6K | 0.27% | 99 |
|
|
2021
Q4 | $844K | Sell |
6,239
-2,579
| -29% | -$305K | 0.23% | 119 |
|
|
2021
Q3 | $951K | Sell |
8,818
-776
| -8% | -$88.7K | 0.21% | 121 |
|
|
2021
Q2 | $1.08M | Sell |
9,594
-944
| -9% | -$106K | 0.21% | 102 |
|
|
2021
Q1 | $1.14M | Sell |
10,538
-8,998
| -46% | -$962K | 0.22% | 88 |
|
|
2020
Q4 | $2.09M | Sell |
19,536
-5,589
| -22% | -$537K | 0.37% | 54 |
|
|
2020
Q3 | $2.2M | Buy |
25,125
+1,623
| +7% | +$153K | 0.45% | 47 |
|
|
2020
Q2 | $2.31M | Buy |
23,502
+13,688
| +139% | +$1.21M | 0.5% | 44 |
|
|
2020
Q1 | $748K | Sell |
9,814
-109
| -1% | -$9.28K | 0.19% | 105 |
|
|
2019
Q4 | $879K | Buy |
9,923
+3
| +0% | +$249 | 0.18% | 105 |
|
|
2019
Q3 | $751K | Buy |
9,920
+633
| +7% | +$43.4K | 0.17% | 108 |
|
|
2019
Q2 | $675K | Buy |
9,287
+270
| +3% | +$21.2K | 0.19% | 91 |
|
|
2019
Q1 | $727K | Sell |
9,017
-1,005
| -10% | -$82.2K | 0.22% | 85 |
|
|
2018
Q4 | $924K | Sell |
10,022
-2,571
| -20% | -$226K | 0.34% | 60 |
|
|
2018
Q3 | $1.19M | Buy |
12,593
+472
| +4% | +$44.8K | 0.35% | 52 |
|
|
2018
Q2 | $1.14M | Sell |
12,121
-10,940
| -47% | -$1.07M | 0.33% | 55 |
|
|
2018
Q1 | $2.18M | Buy |
23,061
+3,891
| +20% | +$427K | 0.63% | 27 |
|
|
2017
Q4 | $2.02M | Buy |
+19,170
| New | +$1.81M | 0.51% | 30 |
|
Other funds holding ABBV
Calton & Associates's ABBV Position: Q2 2026 in Review
Calton & Associates reduced its AbbVie (ABBV) stake by 25% in Q2 2026, selling an estimated $344K and leaving 4,822 shares worth $1.21M. The position accounts for 0.18% of the portfolio, ranked #112.
Calton & Associates first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.31M in Q2 2020. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Calton & Associates held 4,822 shares of AbbVie worth $1.21M as of Q2 2026.
- Calton & Associates sold 1,597 AbbVie shares in Q2 2026, an estimated $344K.
- AbbVie made up 0.18% of Calton & Associates's portfolio in Q2 2026, its #112 holding.
- Calton & Associates first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- Calton & Associates's AbbVie position peaked at $2.31M in Q2 2020.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.